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1. Introduction  
Despite significant progress in medical research, which has led to lower infant mortality 
rates and increased life expectancy, cardiovascular diseases (CVDs) continue to be the 
largest contributors of morbidity and mortality in both developed and developing countries. 
In fact, they are predicted to be the leading cause of death by 2020 and responsible for 13.4% 
of total world-wide deaths by 2030. These diseases have a multifactorial origin, notably non-
modifiable cardiovascular risk factors (CRFs) such as age, sex, race or family history, and 
modifiable CRFs, including smoking, hypertension, hypercholesterolemia, diabetes mellitus 
or hypertriglyceridemia (Picariello et al., 2011; Glynn  &  Rosner, 2005). 
Currently, there are no effective treatments available for many degenerative diseases caused 
by the death or malfunction of specific cells. In this regard, the main physiopathology of 
CVDs is related to ischaemic heart disease, and approximately two-thirds of patients 
surviving an acute myocardial infarction (AMI) are left with debilitating congestive heart 
failure. AMI causes apoptosis and necrosis of cardiomyocytes, a specialized and 
differentiated cell population responsible for ventricular contraction, the main event of 
cardiac function. The low self- renewal rate of these cells (~0.06% of the total population of 
cardiomyocytes under normal conditions) produces, in cases of acute stress, the ventricular 
remodelling of non-ischaemic myocardium with scar formation, increasing the likelihood of 
a new crisis, progressive ventricular dilatation and heart failure, ending in death (Torella et 
al., 2007). 
Organ transplantation is an appropriate therapeutic strategy for patients who have suffered 
end-stage heart failure and are unresponsive to conventional therapy but has drawbacks 
related to donor incompatibility, which can lead to rejection and eventually to Graft Versus 
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Host Disease (GVHD), among other conditions. However, there are a number of 
preoperative and postoperative risks, besides the major challenge of finding an optimal 
donor heart and the elevated healthcare costs involved (currently ranging from 27,839 € and 
51,575 € per patients), especially in view of the uncertain long-term outcomes of the 
procedure (Pérez -Romero et al., 2010). 
1.1 Worldwide costs: The DALY factor 
Besides the elevated mortality rates associated with CVDs, they contribute significantly to 
the burden of disability and disease in developing countries. In an update on the global 
burden of disease in 2004, the WHO provided a comprehensive assessment of the causes of 
loss of health in different regions of the world, demonstrating that the leading cost of the 
death in developed or high-income countries is heart disease, followed by stroke, lung 
cancer, pneumonia and asthma or bronchitis (WHO, 2004). The most widely-used measure 
of this burden is the life expectancy adjusted for disability (DALY), defined as the sum of 
life years lost due to premature death and years lost to disability. CVDs are considered to 
represent 86% of the total DALY-estimated disease burden among under 70-year-olds 
worldwide, indicating that global CVD-related deaths will rise from the 16.7 million 
estimated in 2002 to 23.3 million in 2030. 
1.2 Regenerative biomedicine: Breaking down old paradigms? 
Over the past decade, new therapeutic strategies have been proposed against diseases with 
an elevated prevalence world-wide for which standard treatments are not very effective, 
resulting in the emergence of a new medical science known as regenerative medicine. 
Scientific evidence has demonstrated that novel therapeutic solutions can be obtained for 
pathological situations with no current treatment and that existing therapies can be 
enhanced by the utilization of autologous or allogeneic stem cell transplantation. These 
derive from the discovery of adult stem cell populations in organs well known for their non-
existent regeneration capacity, such as the heart and brain, which correlate with their early 
development in the embryo stage. Thus, some cardiomyocytes with proliferative capacity 
have been found in the heart after a myocardial infarction, although inadequate to meet 
requirements after an extensive AMI. 
The discovery of multipotent cell populations in adult tissues has opened up new 
therapeutic possibilities for diseases that do not respond to conventional medical 
treatments. The ethical and legal issues involved in the use of embryonic stem cells (ESCs), 
the recently disclosed plasticity of adult-derived stem cells, their ability to be reprogrammed 
by defined factors into pluripotent stem cells and a greater understanding, thanks to a 
multidisciplinary approach, of the mechanisms underlying stem cell differentiation have led 
to the birth of the “Regenerative Medicine” concept. Unlike many existing products and 
therapies, this approach offers the potential for regenerative rather than merely palliative or 
symptomatic treatment. This novel specialty includes gene therapy, stem cell therapy, 
targeted drug therapy and cell reprogramming. 
This emerging field seeks the maintenance, improvement or restoration of cell function, 
tissues and organs by applying methods mainly related to cell therapy and tissue 
engineering (Greenwood et al., 2006). The ultimate goal is to repair, replace or regenerate 
cells, tissues or organs that have lost their normal function. The essential elements for the 
success of regenerative medicine include cells, soluble molecules and three-dimensional 
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scaffolds that serve as anchor and stimulation for new tissue formation. In relation to CVD, 
the regeneration of vascular and myocardial tissues is considered a primary endpoint to 
limit the consequences of acute and chronic ischaemic heart disorders. Current clinical 
approaches include transdifferentiation techniques and the utilization of organic scaffolds 
(e.g., vessels or even the whole heart) by means of decellularization methods. 
2. Stem cells and cardiovascular diseases 
Stem cells are unspecialized cells that can renew themselves through cell division or can be 
differentiated to become tissue- or organ-specific cells with special functions (Wobus &  
Boheler, 2005). Up to the 8-cell morulla stage, cells in the embryo are totipotent and can 
produce the whole organism. Their utilisation is limited by ethical issues and current 
legislation in developed countries, besides inadequate knowledge of their behaviour and 
action mechanisms and of their impact on the body homeostasis.  
Stem cells derived from the inner cell mass (ICM) of the blastocyst are no longer totipotent 
but they are pluripotent, having the ability to differentiate into all cell types of the body. 
These cells include human embryonic stem cells (hESCs) and induced pluripotent stem cells 
(iPSCs). hESCs are capable of proliferating extensively in an undifferentiated state and in co-
culture on fibroblast ‘feeder’ cells, and have the ability, once removed from feeders and/or 
grown in suspension as aggregates [called EBs (embryoid bodies)], to differentiate towards 
all three germ layers, and they can, in principle, give rise to all cell types of the body. hESCs 
contain factors that can induce reprogramming of the somatic cell nucleus (Allegrucci & 
Young, 2007; Cowan et al., 2005). Therefore, somatic cell fusion with ESCs regenerates 
pluripotent cells. However, pluripotent cells obtained by fusion contain both chromosomes 
from the ESCs and from the somatic cell, causing their post-implantation rejection 
(Takahashi & Yamanaka, 2006). 
iPSC technology  was developed to avoid these problems, generating a new type of 
pluripotent stem cell by directly reprogramming somatic cells rather than using embryos. It 
allows patient-specific stem cells to be obtained by using the same genome as that of the 
individual whose cells have been reprogrammed. Besides adult and foetal dermal 
fibroblasts, iPSCs have been created from multiple human tissues, including lung 
fibroblasts, keratinocytes (Aasen et al., 2008), fibroblast-like synoviocytes (Takahashi et al., 
2007), cord blood (Giorgetti et al., 2009; Haase et al.,2009) , peripheral blood (Loh et al., 2009, 
Ye et al., 2009) mesenchymal stromal cells (Oda et al., 2010), oral mucosa fibroblasts 
(Miyoshi et al., 2010) and T-cells (Loh et al., 2010; Seki et al., 2010). These cells can be 
differentiated and can serve as a cell or disease model or may even lead to future stem cell 
therapies (Dimos et al., 2008, Park et al., 2008). However, there are a number of drawbacks 
in the use of retroviral vectors to create iPSCs, and considerable efforts have been made to 
find alternatives. 
In addition, certain organs have multipotent stem cells with more limited differentiation 
ability (Wobus & Boheler, 2005), including foetal and adult stem cells obtained from bone 
marrow (BM) and postnatal organs and tissues. Stem cells of foetal origin express stem cell 
markers similar to hESCs, while their differentiation potential lies between that of hESCs and 
that of adult stem cells (Pappa & Anagnou, 2009). BM contains two types of multipotent stem 
cells: hematopoietic stem cells (HSCs), which give rise to all blood cell types (Orkin, 2000) and 
human mesenchymal stromal cells (hMSCs), which can be differentiated into multiple 
mesenchymal tissue cell types such as bone, cartilage, fat and muscle cells (Liu et al., 2009).  
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2.1 The quest for an optimal adult stem cell type: Cardiac Stem Cells (CSC) 
Although many different cell types have been considered for myocardial repair, the ideal 
candidate remains elusive. Adult cardiomyocytes are unable to survive, even when 
transplanted into normal myocardium, and the resident population of cardiac progenitors is 
insufficient after AMI. Therefore, researchers continue to search for the optimal cell type for 
myocardial repair, using various types of adult stem cells obtained from different sources, 
such as HSCs, endothelial progenitor cells (EPCs), cardiac stem cells (CSCs), muscle-derived 
stem cells (MdSTs), and MSCs. MSCs are frequently selected for their multiple advantages, 
such as their multiple anatomical localizations, easy isolation and cryopreservation, and 
paracrine potential. 
The characteristics of CSCs make them an excellent candidate for cardiac regeneration. CSCs 
isolated from myocardial biopsies (Smith et al., 2009) express stem cell factor receptor (c-Kit) 
(Bearzi et al., 2007) and stem cell antigen-1 (Sca-1) on their cell surface (Iwakura et al., 2011). 
A direct relationship has been demonstrated between higher patient age and a smaller 
population of these cells, which represents a drawback for their therapeutic application, 
given that the main incidence of CVDs is among the middle-aged. However, intensive work 
is ongoing to activate these cells to proliferate and differentiate in situ using different 
techniques, such as induction with 5-azacytidine (5-aza), a potent inhibitor of DNA 
methyltransferase (DNMT1), in combination with TGF-ǃ1 and vitamin C (Smits et al., 2009). 
Recent proposals include the use of hyperpolarization to differentiate CSCs into the cardiac 
phenotype, changing charges in the membrane potential (specific for each cell type) to 
enhance intracellular calcium levels and calcineurin signalling in CSCs and, more 
importantly, to upregulate the expression of cardiac-specific genes and proteins, leading to 
the formation of spontaneously beating cardiomyocytes (Van Vliet et al., 2010). Nonetheless, 
the specific capabilities of functional cardiac cells from these progenitors need to be more 
thoroughly studied (Gonzales & Pedrazzini, 2009). 
2.2 Adult stem cell transplantation: Paracrine effects or change in phenotype?  
Recently, cell-based therapeutic strategies have been aimed at replenishing the loss of 
myocytes by apoptosis and necrosis and at inhibiting the adverse effects of cardiac 
remodelling (Singla, 2009). Some studies have demonstrated improvement in ventricular 
function as an achievement of cardiac regeneration (Singla, 2009, Kumar et al., 2005). 
However, if a real clinical translation is to be achieved, researchers must follow strict criteria 
for the selection of an appropriate source of stem cells, taking full account of patient safety, 
production methods, and ethical and legal norms. It is necessary to establish an in vitro 
differentiation strategy to transform these cells into functional cardiomyocytes that can 
integrate in a damaged heart and exert therapeutic action. 
The benefits of stem cell transplantation remain controversial and appear to depend on 
three mechanisms. First, the transplanted stem cells must be able to differentiate, even at a 
low rate, into heart or vascular cells. A second mechanism involves the immune and 
paracrine functions of stem cells and their interactions with an environment subject to 
cellular damage, with the transplanted cells having the capacity to induce the secretion of 
growth factors and cytokines that stimulate tissue repair after ischaemic injury, reducing the 
size of infarction. Finally, the pre-treatment of stem cells by transdifferentiation methods has 
been shown to produce a population of cells in pre-differentiated state, allowing their 
acquisition of the cardiac phenotype after transplantation. However, key issues have not yet 
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been elucidated, including identification of the most appropriate cell types or the factors 
released by stem cells and their role in cardiac repair and regeneration. The methods 
described below were conducted using hMCSs, which appear to be promising candidates 
for clinical translation, given their multipotency and ready availability, e.g., via liposuction. 
2.2.1 Direct transplantation and cell tracking  
Cell transplantation is emerging as a potential therapy to treat heart failure. Initial efforts 
have been focused on the cardiomyocytes and skeletal myoblasts. However, the 
mechanisms and the outcomes of transplanted cells during cardiac regenerative therapy 
remain unclear. In order to achieve the optimal concentration of stem cells for repairing the 
myocardial region of interest, cell delivery strategies need to consider different clinical 
settings and local milieus. Stem cells are believed to respond differently according to local 
signalling, and the success of transplantation depends to a large degree on damage 
signalling in the wounded area. In cardiovascular research stem cells have been delivered 
through coronary arteries or coronary veins or by means of peripheral-vein infusion. 
Alternatively, direct intramyocardial injections have been performed, utilizing a surgical, 
transendocardial, or transvenous approach. Delivery strategies also include the mobilization 
of stem cells from the bone marrow by means of cytokine therapy, with or without 
peripheral harvesting. In pre-clinical studies, when BM–derived hematopoietic cells were 
transplanted directly into the hearts of mice with AMI, no transdifferentiated BM–derived 
cardiomyocytes were found in the damaged myocardium. However, cell fusion has been 
found to occur at very low levels between BM–derived cells and host cardiomyocytes 
outside the infarction area (Nygren et al., 2004). A similar approach has been adopted using 
skeletal myoblast precursors. BM-stem cell (SC) transplantation has been the most widely 
used methodology in clinical studies, as shown in Table 1, although its association with 
arrhythmogenesis, among other adverse effects, has generated major controversy about its 
benefits. 
The main problem with these methods is the lack of knowledge on the behaviour and 
integration of the transplanted stem cells. Many studies have relied simply on the presence 
of histological differences between hearts receiving cell transplants compared with non-
transplanted patients (control group). However, the preferred approach is to utilize 
molecular analyses that are able to distinguish donor and host cells. For instance, treating 
donor cells with fluorescent cell-tracking dyes prior to transplantation has been used to 
monitor their survival in vivo. Because there is typically a high degree of donor cell death 
following transplantation, caution must be exercised to ensure that the observed signal 
arises from donor cells rather than from host cells, which have acquired dye released from 
dead or dying donor cells. Intrinsic genetic differences between donor and host cells as well 
as gene transfer have also been employed to monitor cell fate following transplantation (Lee 
& Segers, 2008). Hence, innovative non-invasive imaging techniques to effectively track the 
cells in vivo are vital for the adequate investigation of possible clinical applications, 
furnishing insights into the mechanisms underlying stem cell-based therapy and addressing 
some of the major concerns about translational cardiovascular stem cell therapy. Currently, 
there are three main approaches to stem cell tracking: (1) radioactive labelling for positron 
emission tomography (PET) and single photon emission computed tomography (SPECT) 
imaging, (2) iron particle labelling for magnetic resonance imaging (MRI), and (3) reporter 
gene labelling for bioluminescence, fluorescence, MRI, SPECT and PET imaging. 
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Clinical trial 
identifier 
number 
Trial name 
Number
of 
patients
Cells 
Primary 
end point
Route of cell 
delivery 
Further 
Comments 
NCT00669227 SCAMI 40 BM-SCs LVEF IC 
Prior treatment 
with G-CSF 
NCT00395811 CABG 50 BM-SCs LVEF IC 
Stem Cell 
Therapy 
combined CABG 
NCT00316381 REGENT 200 
Subpopulation of 
CD34+/CXCR4+  
BM-SCs 
LVEF IC  
NCT00587990 PROMETHEUS 45 MSCs Safety 
Transepicar-
dial during 
CABG 
Stem Cell 
Therapy 
combined CABG 
NCT00548613 MESENDO 20 BM-SCs 
New blood 
vessel 
formation
IC/IM 
Combined stem 
cell therapy 
NCT00939042 ALSTER 40 BM-SCs LVEF IC  
NCT00442806 APOLLO 48 ADRCs Safety Intravenous  
NCT00126100 REVIVAL-2 114 
G-CSF-stimulated 
BMSCs/proge-
nitor cells 
Efficacy 
 
Subcutaneous
Evaluation of the 
↑ of circulating 
SC after 
stimulation 
NCT00268307  41 BM-SCs Safety IC  
NCT00289822  75 BM-SCs LVEF IC  
NCT00626145  37 BM-SCs LVEF 
IC  day 7 
post PCI 
Evaluation of 
reperfusion 
therapy for 
STEMI 
NCT00810238 C-Cure 240 
BM- derived 
cardiopoietic cells
LVEF 
Transendocar
dial 
Efficiency of 
vascular 
regeneration in 
patients with 
CAD 
ADRCs: Adipose-Derived Stem and Regenerative Cells; EPC: Endothelial progenitor cells; BM-SCs: 
Bone Marrow stem cells; MSCs: Mesenchymal stromal cells; G-CSF: Granulocyte Colony Stimulating 
Factor; STEMI: ST-Elevation Myocardial Infarction; PCI: Percutaneous Coronary Intervention; CAD: 
Chronic Coronary Artery Disease; CABG: Coronary Artery Bypass Graft; IC: Intracoronary; IM: 
Intramyocardial; LVEF: Left Ventricular Ejection Fraction. 
Table 1. Closed/Not  recruiting  autologous cell therapy trials in patients with coronary 
heart disease or AMI 
2.2.2 Paracrine and immunology features  
Two important features of MSCs are their immune-privileged and immunosuppressive 
functions. These qualities are very attractive for cell-based therapy because they may 
facilitate the use of allogeneic rather than autologous cells, which offers many potential 
advantages. Thanks to their immunosuppressive capacity, they may also suppress the 
immune response to cell injections or to the damaged myocardium itself during myocardial 
infarction. Findings by Aggarwal and Pittengerin on the lack of T-cell response to allogeneic 
hMSC transplantation indicated that these cells can modify the immune response in a dose-
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dependent manner and can reduce the inflammatory response when present in appropriate 
amounts. Phase III clinical trials are under way on the optimal MSC regimen to prevent or 
treat GVHD during allogeneic HSC transplantation (Aggarwal & Pittenger 2005). 
Secreted growth factors and cytokines are known to be important signalling molecules for 
modulating acute and chronic immune responses (Table 2). With regard to their 
immunomodulatory properties, MSCs inhibit T-cell proliferation and influence the maturation 
and expression profile of antigen-presenting cells such as dendritic cells. Research on the 
paracrine effect of MSCs in rat AMI models, using intramyocardial injection of culture 
medium with MSC-secreted growth factors and cytokines (conditioned medium), 
demonstrated their role in stromal network creation, neovascularization enhancement, 
angiogenesis promotion, and cardiac function improvement. Paracrine effects of MSCs may 
include the activation of different mechanisms against cell damage. Therapeutic models have 
shown that MSCs are recruited to infarction areas by the hepatocyte growth factor (HGF), 
which is released during necrosis and apoptosis and acts as a “homing signal”. This migration 
of MSCs depends on interaction with c-Met, an HGF receptor (Parekkadan & Milwid, 2010).  
 
Growth factors and cytokines Functions References 
M-CSF, G-CSF, GM-CSF, SCF-1, 
LIF, SDF-1, Flt-3, IL 1, 6, 7, 8, 11, 
14 and 15. 
Signalling molecules 
and modulation of 
acute and chronic 
immune response. 
Sumanasinghe et al., 2009 
Kim et al., 2005. 
VEGF, bFGF, PLGF and MCP-1. 
Vasculogenesis and 
angiogenesis 
Kinnaird et al., 2004. 
M-CSF: Macrophage Colony-Stimulating Factor; G-CSF: Granulocyte Colony-Stimulating Factor; GM-
CSF: Granulocyte Macrophage Colony-Stimulating Factor; SCF-1: Stem Cell Factor; LIF: Leukemia 
Inhibitory Factor; SDF-1: Stromal Cell-Derived Factor-1; Flt-3: FMS-like tyrosine kinase 3; IL: 
Interleukin; VEGF: Vascular Endothelial Growth Factor; bFGF: basic Fibroblastic Growth Factor; PLGF: 
Placental Growth Factor; MCP-1: Monocyte Chemoattractant Protein-1 
Table 2. Paracrine activity of MSCs 
MSC-derived conditioned medium promotes the proliferation of CSCs and inhibits the 
apoptosis of CSCs induced by hypoxia and serum starvation. An upregulated expression of 
cardiomyocyte-related genes was also found in CSCs, including b-myosin heavy chain (b-
MHC) and atrial natriuretic peptide (ANP), demonstrating the protective effects of this 
medium on CSCs and the enhancement of their migration and differentiation (Nakanishi et 
al., 2008). Preliminary results of in vitro assays with human adipose-derived mesenchymal 
stromal cells (hADSCs) by our group indicate that cytokine- and growth factor-rich 
conditioned media obtained from human cardiomyocytes in culture influence the 
acquisition of cardiac phenotype by hADSCs (unpublished data). 
2.2.3 Cardiac regeneration: A transdifferentiation phenomenon  
Regenerative biomedicine efforts have focused on attempts to reverse heart muscle failure 
by increasing the amount of human functional heart muscle through the transplantation of 
various adult stem cell types, notably CSCs, skeletal myoblasts, endothelial stem cells, and 
MSCs. BM stem cells have been reported to offer a wide range of benefits in blood cell 
diseases, but the action mechanisms underlying the change in phenotype have not been 
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clarified. In vivo transplantation studies have shown that MSCs can replenish the whole BM 
system in irradiated rodents and generate not only mesodermal cells but also cells with the 
characteristics of neural progenitors and neurons (Song & Tuan, 2004). 
In this type of cross-lineage differentiation, also known as transdifferentiation, one cell type 
committed to and progressing along a specific developmental lineage is switched into 
another cell type from a different lineage by genetic reprogramming. This depends on the 
ability of adult stem cells to maintain their multidifferentiation potential even after exposure 
to specific inductive factors (Song & Tuan, 2004). 
The conversion from adult differentiated cells must involve both the suppression and 
regulation of different genes in the cells, implying that genes from both cell types are co-
expressed at some point. This phenomenon is currently under investigation by various research 
groups in an attempt to establish its true therapeutic value. Transdifferentiation studies have 
supported the notion that cell fate is controlled by master switch genes and that one or two 
factors can be sufficient to direct cells from one lineage to another (Burke & Tosh, 2005). 
 
 
Fig. 1. Guided cardiopoiesis. This diagram depicts the effects of cytokines in MSCs cultures.  
This process involves cardiopoiesis, defined as the final engagement of pluripotent or 
multipotent stem cells in the cardiac differentiation program. Cardiopoietic specification is 
based on emulation of the natural cardiac development in the embryo, which takes place in 
the mesoderm under the cardioinductive influence of the neighbouring endoderm (Figure 
1). Cardiopoietic guidance emulates natural cardiac differentiation and can be achieved by 
stimulating stem cells with TGF-ǃ1, BMP-2/4, FGF-2/4, IL-6, IGF-1/2, VEGF-A, EGF and 
activin-A. The identification of these factors has enhanced our understanding of the 
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mechanisms involved in differentiation and the signals that play a role in heart development 
(Behfar et al., 2010). 
3. From the bench: Current status  
Greater knowledge of heart development in the embryo and of the effects of the 
microenvironment on cardiac maturation has prompted researchers to reproduce these 
processes in the laboratory by means of different transdifferentiation techniques (Figure 2). 
Some of them have attempted to recapitulate the activation of cell signalling cascades 
involved in heart development (e.g., TGF-ǃ and Akt) through the expression of GATA4, 
Mef2c and FGF 8/10 growth factors. A wide range of cell types and methods have been 
used to achieve the cardiac phenotype. In this regard, there is major interest in the novel 
technique developed by Takahashi & Yamanaka (2006), to induce pluripotency by 
reprogramming fibroblasts with key factors Klf4, Sox2, Oct4 and c-Myc. It is expected that 
the ability to derive patient-specific hiPSCs by somatic cell reprogramming may be useful 
for disease modelling and drug discovery as well as basic research. 
 
 
 
Fig. 2. Methods used to transdifferentiate MSCs to cardiomyocyte like-cells 
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3.1 Transdifferentiation methods using adult stem cells  
3.1.1 Use of allograft cardiac tissue: The co-culture and cell extracts methods  
The co-culturing of two different cell types, such as cardiomyocytes isolated from human 
biospies and hMSCs, which are grown together but separated by a membrane (with 0.4 – 0.3 
μm pore size to avoid direct cell-to-cell interaction), has revealed the importance of the 
microenvironment in stem cell differentiation. This method is used to determine whether 
soluble chemical factors released from one cell type (which can diffuse though the 
membrane) are sufficient to induce transdifferentiation of the other cell type. Using this 
mechanism, Wang et al. (2006) showed in vitro the differentiation of BM stem cells into 
cardiomyocyte-like cells with expression of cardiac-specific genes. Similar results have been 
obtained by various authors (Antonitsis et al., 2007; Rangappa et al., 2003).  
In the cell extract method, the intracellular components of one cell type are introduced into 
another cell type in order to switch from one cell pattern to another. Purified somatic nuclei 
or reversibly permeabilized somatic cells are incubated in a nuclear and cytoplasmic extract 
derived from a different cell type. The extract is believed to provide nuclear regulatory 
components that mediate alterations in the gene expression profile of the target genome. 
After exposure to the extract, the cells are resealed in a culture that contains calcium. By this 
means, hADSCs produced cardiomyocyte proteins after incubation with rat cardiomyocyte 
extracts. The success of these transdifferentiation strategies was demonstrated by 
observations of morphological changes, by findings on donor cell-specific genes, and by 
immunological evidence of alterations in protein expression (Gaustad et al., 2004). 
Our group reported that adult cardiomyocytes obtained from human donors retain their 
capacity to induce cardiomyocyte differentiation of MSCs. Human adipose stem cells 
(hASCs) isolated from lipoaspirates were transiently permeabilized, exposed to human 
atrial extracts and then allowed to recover in culture. After 21 days, the cells acquired a 
cardiomyocyte phenotype, as demonstrated by morphologic changes (appearance of 
binucleate striated cells and branching fibbers), immunofluorescence detection of cardiac-
specific markers (connexin-43, sarcomeric ǂ-actinin, cardiac troponin I and T and desmin) 
and the presence of cardiomyocyte-related genes (cardiac myosin light chain 1, ǂ-cardiac 
actin, cardiac troponin T and cardiac ǃ-myosin). The relevance of these findings lies in the 
potential use of autologous extracts to induce stem cell reprogramming (Perán et al., 2010). 
In conclusion, both techniques have an interesting potential in a therapeutic framework, due 
to their capacity to avoid immunologic responses from patients and produce a good clinical 
outcome. 
3.1.2 Use of 5 –azacytidine and growth factors  
The acquisition of a cardiac phenotype has been induced by the use of demethylation agents 
such as 5-aza, a cytosine analogue that can reduce DNA methyltransferase activity in the 
cells (Quian   et al., 2011). However, in vivo studies with 5-aza showed that specific proteins 
were expressed in myocytes near the injection site in the myocardium, but these cells lacked 
the complete acquisition of cardiac phenotype and were not capable of symmetric 
contraction (Valiunas et al., 2004). Similar methods have been reported to produce cells with 
cardiomyocyte phenotype from human adipose-derived stem cells, and spontaneously 
beating cells were obtained after co-culture with neonatal rat cardiomyocytes (Choi et al., 
2010).  
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3.1.3 Genetic modifications: Use of viral vectors  
The genetic modification of MSCs is an interesting option for improving their therapeutic 
potential. The transfection of master genes or transcription factors that induce 
differentiation into the cardiac phenotype was recently developed as a transdifferentiation 
methodology. In cardiac research, efforts have been made to transfect BM-MSCs with viral 
constructions, using retroviral vectors that contain the master genes Csx/Nkx2.5 and 
GATA-4. Single-cell-derived MSCs overexpressing Csx/Nkx2.5 and GATA4 behaved as 
cardiac transient amplifying cells and retained their plasticity in vivo, but 5-aza treatment 
was required to achieve a complete cardiac phenotype. The frequency of cardiomyogenic 
differentiation was increased by co-culturing with foetal cardiomyocytes (Yamada et al., 
2007). 
For human clinical proposes, Ad- vectors are safer than RV- vectors because they do not 
integrate into the cellular DNA, and therapy with Ad-transduced MSCs is likely to be less 
immunogenic than the direct administration of Ad-vectors to affected tissues, due to the 
anti-inflammatory properties of MSCs. Moreover, transgenic expression in proliferating 
stem cells is only transient, due to the non-integrative properties of Ad-vectors. Nonetheless, 
short-term therapeutic gene expression may be sufficient or even desirable for the treatment 
of diseases such as myocardial infarction, in which the transient paracrine effects of MSCs 
enhance tissue healing and repair responses (Reiser et al., 2005). 
Two studies recently reported the direct reprogramming of murine fibroblasts into 
functional cardiomyocytes. Srivastrava´s group developed a method to recruit and 
transdifferentiate resident cardiac fibroblasts near the infarction area. This group enforced 
the expression of developmental cardiac transcription factors Gata4, Mef2c, and Tbx5 and 
produced cardiomyocytes that matched a normal cardiomyocyte gene expression profile 
(Ieda et al., 2010). The efficiency of this direct reprogramming was higher in comparison to 
reprogramming to iPSCs (20% vs. <0.1%) and it was more rapid, but the emergent 
cardiomyocytes could not be expanded in culture, which is a shortcoming. 
In another study, Ding´s group obtained cardiomyocytes by virally transducing mouse 
embryonic fibroblasts with genes encoding for the transcription factors Oct4, Sox2 and Klf4, 
followed by modified standard reprogramming medium, in which leukaemia inhibitor 
factor was removed and foetal bovine serum was added at 1-15% (Efe et al., 2011). This new 
development may help eliminate some of the obstacles to the use of traditional ESCs or 
iPSCS, including teratoma formation due to residual undifferentiated cells, and it may lower 
the cost and delivery time to patients thanks to higher yields and faster production. 
3.2 Transdifferentiation methods using iPSCs  
Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically 
reprogrammed to an embryonic stem cell-like state by being forced to express genes and 
factors important for maintaining the defining properties of embryonic stem cells. The 
reprogramming of adult cells into ESCs enables the generation of patient-specific stem cells 
and therefore has enormous potential for the analysis and treatment of degenerative 
diseases. iPSCs are typically derived by transfection of certain stem cell-associated genes 
into non-pluripotent cells, such as adult fibroblasts. Transfection is typically achieved 
through viral vectors, such as retroviruses. Transfected genes include the master 
transcriptional regulators Oct-3/4 (Pouf51) and Sox2, although some other genes (e.g., Klf4, 
c-Myc) have been used to enhance the efficiency of induction.  
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Among various methods used to induce differentiation in pluripotent cell lines, the most 
widespread is to grow undifferentiated cells as aggregates in suspension, which causes them 
to form EBs in which cardiac cells spontaneously develop (Son et al., 2011). Cardiomyogenic 
mesodermal progenitors are normally formed in the embryo during gastrulation as cells of 
the epiblast pass through the primitive streak (Nury et al., 2009). 
Many protocols for directed differentiation to cardiomyocytes are based on these 
developmental principles. In general, two directed differentiation strategies have been 
applied. First, the co-culture of hESCs with cardio-inductive cell types, such as endodermal 
cell line END-2. Cardiac induction by END-2-conditioned medium can be (partly) mimicked 
by insulin depletion (Freund et al., 2008), inhibition of p38 MAPK (Graichen et al., 2008) and 
addition of prostaglandin E. 
A second method is to induce gastrulation by the use of specific growth factors. Several 
studies have shown that various combinations of BMP4, WNT3a and Activin A induce 
gastrulation-like events and meso-/endoderm development in hESCs (Sumi et al., 2008; 
Vijayagavan et al., 2009). A similar approach uses an efficient cardiac differentiation 
protocol based on transient stimulation with BMP4, bFGF and activin A followed by VEGF 
and WNT inhibition through DKK. Both approaches have allowed considerable progress to 
be made over the past few years with respect to the efficiency of cardiomyocyte 
differentiation, but its use in clinical therapies remains plagued with numerous problems, 
including inadequate purity. The same methods are currently used for the generation of 
iPSCs-derived cardiac cells. 
3.2.1 Future applications of iPSCs technology in heart disease 
The possibility of creating patient-specific embryonic stem cell-like cells may complement 
the rather slow development of heart disease models based on hESC. However, their value 
in elucidating disease mechanisms and as models for drug discovery remains to be 
demonstrated. The uniformity and reliability of the differentiation of several well-studied 
hESC lines may make these the most useful near-term research tool; therefore, research on 
the targeting and genetic modification of hESCs is still vital. In this regard, the use of iPSCs 
models has opened a new alternative to study illness, especially in countries were legal 
issues do not allow the use of hESC. 
The generation of heart disease models is a highly complicated process, due to the variety of 
aetiologies and subtypes of CVDs and their complexity. Initial approaches have avoided 
multi-gene diseases and focussed on heart diseases associated with mutations in single 
genes, which are most likely to have an effect at single cell level. This is the case of 
channelopathies, which are related to mutations in a small set of genes that encode cardiac 
ion channels and sarcomeric proteins. In this way, the phenotypes of these diseases are 
characterized by disturbed ion channel function (cardiac channelopathies) or impaired 
contractility (cardiomyopathies). Heritable cardiac channelopathies include long-QT 
syndrome (LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular 
tachycardia, cardiac conduction disease and sinus node dysfunction (Priori & Napolitano, 
2006. 
Recent successes have been reported using human iPSCS as models for human heart 
disease. Two groups generated human iPSCS lines from heart disease patients that showed 
a disease phenotype in culture. Carvajal-Vergara et al. (2010) produced cardiomyocytes 
from two human iPSCs lines derived from two patients with a heterozygous T468M 
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substitution in PTPN11 (protein tyrosine phosphate, non-receptor type 11), which leads to 
Leopard syndrome, offering novel insights into signalling pathways related to this disease. 
Another study by Moretti et al. (2010) investigated an ion channel mutation in patients with 
LQT1. LQTS is a life-threatening congenital condition characterized by cardiac arrhythmias 
and sudden cardiac death. These patients have a KCNQ1 gene mutation that results in an 
elongated QT-interval. The KCNQ1 gene encodes IKs, the ion channel controlling the slow 
component of the delayed rectifier K+ current, which is partially responsible for the 
repolarising phase of the action potential. The authors were able to recapitulate this 
electrophysiological phenotype in culture by using a whole-cell patch-clamp 
electrophysiology method after creating human iPSCs lines from two patients in a single 
family with an R190Q missense mutation in KCNQ1. Using a similar method, Itzhaki et al. 
(2011) developed a patient/disease-specific human iPSCs line from a patient with type-2 
LQTS, which is due to the A614V missense mutation in the KCNH2 gene, coaxing these 
iPSCs to differentiate into the cardiac lineage. The LQTS human iPSC-derived cardiac-tissue 
was used as a model to evaluate the potency of existing and novel pharmacological agents 
that may either aggravate (potassium-channel blockers) or ameliorate (calcium-channel 
blockers, KATP-channel openers and late sodium-channel blockers) the disease phenotype. 
4. Pre-clinical studies: A step to the bedside 
Initial animal experiments found that the transplantation of BM-SCs after AMI and 
ischaemic cardiomyopathy is associated with a reduction in scar size and improvements in 
the ejection fraction of the left ventricle (LVEF) and tissue perfusion (Dawn & Bolli, 2005). 
Other pre-clinical studies demonstrated an improvement in myocardial function after repair 
of the infarcted area through implantation of EPCs derived from peripheral blood, BM or 
umbilical cord blood (UCB) (Leor & Marbel, 2006; Perin & López, 2006). 
MSCs have also been used in a model of chronic myocardial ischaemia in large animals. 
Twelve dogs that received intramyocardial injections of 100 million cells showed improved 
systolic function (by echocardiography) in comparison to controls, both at rest and under 
stress situations; in addition, the MSCs were able to transdifferentiate into endothelial cells 
and smooth muscle cells, enhancing vascularization (Perin et al., 2003).  Skeletal myoblasts 
were also studied in the setting of chronic myocardial ischaemia, specifically to treat 
myocardial scarring, and were found to improve the LVEF and the adverse effects of 
ventricular remodelling, due to their high capacity to engraft in scarred myocardial 
segments (Leor et al., 1996). 
5. To the bedside: Cardiac cell therapy 
The rapid development of stem cell technology has raised hopes for novel and even 
revolutionary treatments for cardiac and other disorders with tissue damage, awakening the 
keen interest of the pharmaceutical industry. These expectations are largely based on the 30-
year history of successful BM-HSC transplantations in patients with blood diseases and 
cancer (Thomas et al., 1959; Shizuru et al., 2005). However, few stem cell therapies have been 
widely accepted by the medical community, and all of these use tissue-specific stem cells. 
These include BM or UCB stem cell transplantation to treat blood diseases or restore the 
blood system after cancer treatments, skin stem cell therapies for burns and limbal stem cells 
for corneal replacement, among others. In each case, stem cells repair the same tissue as that 
from which they are derived. 
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Cardiac cell therapy has been attempted in more than 1000 patients worldwide, and the 
results of the first meta-analysis recently became available. The interest in the use of adult 
stem cells in cardiac regeneration began after the demonstration by Orlic et al. (2001a) that 
murine BM-derived cells regenerated heart muscle after direct injection at the site of the 
previously induced myocardial infarction. These promising results generated significant 
interest in its clinical application, with the launch of numerous randomized clinical trials on 
the efficacy of cell therapy in patients with coronary disease, including 37 trials in Europe 
alone. The interpretation of their results should consider the effectiveness of the cell 
transplantation method, the delivery time and the cell type used. In this section, the NIH-
supported ClinicalTrials website (ClinicalTrials.gov) was searched for closed and ongoing 
clinical trials in the field. Keywords included “heart”, “myocardial infarction”, “heart 
failure” and “cell therapy” (Table 3). 
5.1 Bone marrow-derived stem cells 
The TOPCARE-AMI study provided the first major clinical report on the transplantation of 
BM stem cells after myocardial infarction (Leistner et al., 2011). Patients were randomized to 
receive BM-derived mononuclear cells (29 patients) or EPCs (30 patients) by intracoronary 
infusion. Both groups showed improved LVEF at 4 months and reduced infarct size at 12 
months, but there was no randomized control group with which to compare results. More 
recently, in a sub-group of the same patients, the authors observed a significant increase in 
LVEF (by cardiac MRI) and a reduction in infarct size (by delayed enhancement MRI). 
Interestingly, the migratory capacity of the infused cells proved to be the most important 
predictor of myocardial remodelling (Britten et al., 2003). 
Some trials failed to show a significant increase in cardiac function, whereas others 
evidenced improvements comparable with those obtained by established treatment 
regimens (Reffelmann & Kloner, 2009). A range of results has been reported, from a low to a 
14% improvement in LVEF (Fernandez-Aviles et al., 2004; Perin & López, 2006; Stamm et al., 
2007; Tatsumi et al., 2007).  
Many clinical studies have evaluated the therapeutic potential of human BM-derived stem 
cells (e.g. MSCs or mononuclear cells) to improve cardiac function after myocardial 
infarction (Gonzales & Pedrazzini, 2009; Mathiasen et al., 2009; Wei et al., 2009). However, 
no evidence has been reported of cardiac regeneration through differentiation of implanted 
stem cells into cardiomyocytes and other cardiac cell lineages. Some studies, but not all, 
have reported beneficial effects on heart function and on symptoms (Janssens et al., 2006; 
Lunde et al., 2006; Schachinger et al., 2006; Meyert et al., 2006). However, it has been 
suggested that these benefits are short-term, and a five-year follow-up study found that 
treatment with BM cells did not achieve sustained improvements in heart function (Meyer et 
al., 2009). Nonetheless, according to the results of all of these studies, the therapeutic use of 
human BM stem cells appears to be safe. 
A meta-analysis of 18 randomized and non-randomized clinical trials, including 999 patients 
with AMI and chronic ischaemia, reported encouraging results after the transplantation of 
BM-MSCs. In comparison to controls, the transplantation improved the LVEF by 5.40% (P 
<0.001), reduced the post-AMI scar area by 5.49% (P = 0.003) and reduced the left 
ventricular end-systolic volume by 4.80 ml (P = 0.006). According to the results of this meta-
analysis, BM-MSC therapy appears to be safe and can be used in large-scale randomized 
trials to assess its impact on cell therapies (Abdel-Latif et al., 2007). 
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Clinical trial  
identifier 
number 
Trial 
name/ 
Sponsor 
Expected 
enrolment
Acquisition  
Method/ 
treatment 
Primary 
end point 
Route of cell 
delivery 
Further Comments 
Cardiac Stem Cells 
(CSCs) 
    
 
NCT  
00474461 
 
SCIPIO 
 
40 
 
Harvested 
from RAA 
 
LVEF 
 
IC 
Evaluation of the 
regeneration 
capacity of CSCs in 
non-viable 
myocardial 
segments in 
patients with ICM 
 
NCT 
00981006 
 
ALCADIA
 
6 
 
Clonally Cell 
isolation 
 
Safety 
 
IM 
Stem Cell  
Therapy combined  
with bFGF release  
and using a  
gelatin Hydrogel 
Sheet during  
CABG 
NCT 
00893360 
CADUCEUS
 
30 Harvested 
from biopsies
LVEF IC Evaluation of the 
regeneration 
capacity of CSCs 
Skeletal Myoblasts 
(SMs) 
     
NCT  
00526253 
MARVEL170 Unknown LVEF Catheter 
delivery 
system 
Evaluation of  
Myocell™ effects 
NCT  
00102128 
Genzyme 30 Harvested 
from the 
thigh muscle
LVEF Unknown Evaluation of the 
regeneration 
capacity of SM 
NCT  
00908622 
PERCUT
ANEO 
50 Harvested 
from biopsies
LVEF PercutaneousCardiomyoplasty 
benefits with 
 SMs in  
patients with old 
AMI. 
Endothelial Progenitor Cells (EPCs)    
 
NCT  
00936819 
 
ENACT-
AMI 
 
100 
Harvested 
from 
apheresis, 
One group 
transfected 
with eNOS 
 
LVEF 
 
IC  into the 
IRA 
 
Combined Cell and 
gene therapy 
RAA: Right atrial appendage; IRA: Infarct Related Artery; ICM: Ischaemic Cardiomyopathy; bFGF: 
Basic Fibroblastic grow factor; CABG:  Coronary Artery Bypass Graft; eNOS: human endothelial nitric 
oxide synthase 
Table 3. Ongoing clinical trials using different autologous stem cells. 
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5.2 Mesenchymal stromal cells  
Animal studies are ongoing to determine whether MSCs can be used to treat arthritis, non-
healing bone fractures or spinal cord injuries, among other diseases. Although it is also 
possible that these or similar cells modulate the immune system in response to injury, their 
use as cardiomyocyte-like cells via transdifferentiation methods remains controversial. A 
major advance in this field was achieved by Behfar et al. (2010), whose results with MSCs 
using guided cardiopoiesis methods allowed this approach to be evaluated in preclinical 
studies. They obtained a complete cardiac phenotype by using an endoderm-like protein 
cocktail with hMSCs harvested from patients with coronary artery disease. The hMSCs were 
injected into the myocardium of nude infarcted mice and followed up for a year to assess 
functional and structural endpoints. The recombinant cardiogenic cocktail guidance secured 
the cardiopoietic phenotype across the patient cohort, achieving a superior functional and 
structural benefit in comparison to unguided counterparts, with no adverse side effects 
(Behfar et al., 2010). 
However, there is evidence of a low retention of the infused cells in the area of interest, 
which would reduce the effectiveness of this approach. Current strategies include the use of 
hMSCs modified with viral vectors carrying genes that increase the affinity of these cells to 
the sites of cell damage, e.g., through activation of HIF-ǂ factor, which is expressed in states 
of hypoxia (Xue et al., 2010).  
5.3 Skeletal myoblasts  
The promising experimental results achieved by Leor et al. (1996) with skeletal myoblasts in 
a chronic myocardial ischaemia model, described above in section 4, generated significant 
interest in their possible clinical application. The first clinical trial was conducted at Paris-
Descartes University using autologous skeletal myoblasts isolated from muscle biopsies 
from patients with severe heart failure, expanded ex vivo and then transplanted. The clinical 
status and ejection fraction of the treated patients improved over time, with a strikingly low 
incidence of hospitalizations for heart failure (0.13/patient-years). Moreover, the risk of 
arrhythmia could be controlled by medical therapy and/or on-request automatic cardiac 
defibrillator implantation (Menasche et al., 2001).  
Therapy with skeletal myoblast transplantation was tested in the MAGIC trial (Myoblast 
Autologous Grafting in Ischaemic Cardiomyopathy). An injection of stem cells or culture 
medium was randomly administered to patients and, although initial fears of serious 
arrhythmias did not materialize, the results showed no significant benefit from the stem cell 
treatment. 
The ambiguous results of clinical trials reflect differences due to the diversity of cell types 
and administration routes used. The timing of the assessment of ventricular function post-
transplantation may also explain some discrepancies in the results. Several of the benefits 
achieved by this therapy appear to be transient (Meyer et al, 2009), consistent with the 
findings of similar studies conducted in animals (van Laake et al., 2008). 
5.4 iPSCs technology  
The need for deeper knowledge of iPSCs is acknowledged by the scientific community, but 
only one clinical trial is using this cell type, in an attempt to induce pluripotent stem cells 
from cell cultures of skin biopsies (Royan Institute, Iran, CI. NCT00953693). This trial is 
related to hepatic regeneration. The strategy is basically the same for all research purposes: 
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after isolation of fibroblasts from the patient`s skin biopsy, the cells are transfected after 3-4 
weeks with the four factors used by Yamanaka. Transfected cells are isolated by 
morphological selection in order to generate allogeneic hiPSCs (Seifinejad et al., 2010). In the 
field of heart disease, basic research includes aspects such as the generation of 
cardiomyocytes derived from human ES/iPS cells from post-AMI heart failure patients 
(Itzhaki et al, 2011). These results will be important for drug discovery screening in relation 
to QT prolongation and cardiac cell transplantation therapy. 
6. Funding research through industry: Development of patents in cell therapy 
Improved understanding of the development of the human heart has led to proposals for 
strategies that emulate the cardiogenic programme, which are currently being tested in pre-
clinical and clinical studies. There are an increasing number of patents in this area as well as 
on the establishment of cell lines. A patent operates as a quid pro quo: the patent owner 
obtains the exclusive right to make, use and sell an invention in exchange for its public 
disclosure. Some scientists believe that patents harm the research environment by increasing 
secrecy and costs. Others consider that the regenerative medicine sector requires access to 
funding and resources for the protracted procedures required, including not only the 
research and clinical trials but also the legal issues that must be addressed with respect to 
patent protection for regenerative medicine-related intellectual property. Interestingly, 
regenerative medicine may change the conventional reliance on patents and their finite 
exclusivity, which is a truly major issue for the pharmacy industry. Patent registers in the 
USA show a growing number of patents for the treatment of CVDs using stem cells, 
representing a validation of the therapeutic potential of this approach. In Europe, there is a 
slight trend towards the creation of patents related to methods for isolating cell populations 
with cardiopoietic potential and for preparing enrichment culture media, which are in pre-
clinical stages of application.  
A search of the sources “Patent Lens” of the organization “Initiative for Open Innovation 
(IOI)”, “Patentscope” of the World Intellectual Property Organization (WIPO), and the 
“Invenes”, “Esp@cenet”, “Free patents online” and “Latipat” databases of the Spanish 
Patents Office, shows that  patent applications to commercialise cell therapies for CVDs 
centre on three main topics: i) methods to deliver stem cells to the damaged myocardium, ii) 
methods to isolate and differentiate autologous cells harvested from patients, and, finally, 
iii) viral vectors for gene delivery. 
6.1 Achieving the cardiac cell phenotype: Producing stem cell- derived 
cardiomyocytes 
Given the difficulty of isolating and culturing heart cells, many studies have focused on 
developing methods to induce the differentiation of stem cells into the myocardial 
phenotype. For this purpose, MSCs are the most widely used cells in the patents and clinical 
trials reviewed, followed by HSCs, but knowledge of the existence of cardiac progenitor 
populations has made these the object of the most recent studies. One example is the 
development by Chien  et al.  (2011) (Patent application US 2011/0003327) of methods to 
identify and isolate atrial progenitors and, in some cases, atrial progenitors that are positive 
for Islet 1 (Isl1) and sarcolipin, which are growth factors responsible for the negative 
regulation of second heart field progenitor cell differentiation (Buckingham et al., 2005). 
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Another invention of this team relates to methods for isolating cardiovascular stem cells, 
placing cell populations in contact with agents reactive to Isl 1, Nkx2.5 and Flk-l and 
separating reactive from non-reactive cells (Chien & Chang 2008; Patent application WO 
2008/054819 A2). 
The use of MSCs from different sources is reflected in the patent of Büscher et al. (2010) (US 
patent application 20100304477), who characterized a novel population of human cardiac 
adipose tissue-derived adult stem cells from the epicardial area. These cells are isolated by 
their surface marker profile and their gene and protein expression of different cardiac 
muscle cell components, including the cardiac factors GATA-4 and Nkx2.5, the sarcomere 
components beta-myosin heavy chain and ǂ-actinin, and the regulators of electrochemical 
connection and intracellular calcium distribution, connexin-43 (Cx43) and SERCA-2, 
respectively. 
6.2 How can stem cells be guided to the damaged myocardium? 
Numerous techniques have been developed for this purpose, including the use of growth 
factors and molecules that deliver and mobilize stem cells to the injured site. This paracrine 
effect has been described in MSCs and also includes the activation of different mechanisms 
against cell damage. In this respect, granulocyte colony-stimulating factor (G-CSF) has 
proven useful alone or in combination with the stem cell factor (SCF) in the mobilization of 
BM stem cells. The pre-AMI mobilization of primitive BMCs by the administration of G-CSF 
and SCF (US Patent 7220407) results in a significant degree of tissue regeneration at the 
ischaemic site (Orlic et al., 2001b). It is also contemplated that human G-CSF therapy may be 
used in a similar manner along with other agents commonly used for the treatment of AMI 
in conjunction with reperfusion. 
In the field of gene therapy, several methods have been developed for treating patients with 
CVDs, including heart disease and peripheral vascular disease. The preferred methods 
involve the in vivo delivery to the myocardium or peripheral ischaemic tissue of genes 
encoding angiogenic proteins or peptides by the introduction of a vector containing the gene 
into a blood vessel supplying the heart or into peripheral ischaemic tissue. The patent 
“Techniques and compositions for treating cardiovascular disease by in vivo gene delivery” 
(Hammond et al., 2003; US Patent Application 20030148968), describes a method that 
employs a replication-deficient adenovirus as vector. By injecting the viral vector stock with 
angiogenic protein- or peptide-encoding genes deeply into the lumen of one or both 
coronary arteries or grafts, it is possible to locally transfect an adequate number of cells, 
especially cardiac myocytes, into the affected myocardium. This methodology maximizes 
the therapeutic efficacy of gene transfer and minimizes undesirable angiogenesis at 
extracardiac sites and the possibility of an inflammatory response to viral proteins. 
7. Clinical translation 
The translation of research findings to the clinical setting can be a complex process. This 
discipline, based on interventional epidemiology, aims to increase the throughput of 
findings from the basic or early phase of clinical research in ageing and to use them to drive 
innovation in healthcare settings. The success of clinical translation depends on the capacity 
of scientists, clinicians, regulators and other experts to share their expertise with one other 
and on their ability to respond adequately to negative or positive clinical outcomes. 
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In the field of CVD, considerable efforts have been made to establish feedback between 
research groups and clinical practice. Universities and hospitals have developed clinical 
translation units in which stem cell-related issues are focused on the utility of plasma 
biomarkers of acute brain injury to improve the early diagnosis of acute stroke and on the 
prevalence and specific causes of ventricular repolarisation abnormalities in older patients 
undergoing psychoactive drug treatment, among others. 
7.1 Cell therapy  
As reported above, human cell-based medicine is proving increasingly attractive to the 
pharmaceutical and medical equipment industries, opening up the way for the self-funding 
needed for scientific development and the implementation of clinical trials. This is of 
particular importance at a time of intense pressure to reduce public health costs. 
Progress has been made in developing protocols for obtaining and isolating stem cells, in 
establishing legislation that specifies the parameters of good manufacturing practice for 
large-scale production, and in accumulating pre-clinical data that validating the effects of 
this therapy. As a result, several types of stem/progenitor cells have been proposed for use 
in regenerative medicine, leading to the consideration of stem cells as pharmaceuticals. 
Large pharmaceutical companies apply stem cell-based technologies and other proprietary 
methods in the area of regenerative medicine to bring patient-specific therapies from the 
laboratory to the bedside. This is the case of products being developed by Advanced Cell 
Technology, Bioheart Inc. and Cardio3 Bioscience companies (Figure 3). 
 
 
Fig. 3. Examples of products in development for cell therapy in diseases related to the 
cardiovascular system. 
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We highlight the initiatives taken by some U.S. drug companies, who have begun to market 
cell therapies after successful clinical trials. One example is Athersys Inc., whose MultiStem 
cell therapy has a broad potential to treat diseases such as AMI, stroke, and inflammatory 
bowel disease. MultiStem promotes tissue repair through the induction of therapeutic 
factors produced in response to signs of inflammation and tissue damage. Likewise, the 
Bioheart company is now marketing MyoCell as a result of the MARVEL trial, a 
randomized, double-blind, placebo-controlled, multicenter, phase II/III trial involving 330 
patients in North America and Europe. MyoCell uses muscle tissue samples from the 
patient, isolating and expanding stem cells and then transplanting them by endoventricular 
injection into the patient’s scar tissue (MyoStar ™). 
7.2 Scaffolding: The development and translation of the tissue-engineered vascular 
graft 
The post-mitotic and myogenic nature of myocardial tissue hampers the in vitro isolation 
and maintenance of cardiomyocytes. In vitro dedifferentiation is evidenced by the loss of 
sarcomeric distribution, observed in the distribution pattern of protein alpha actinin, 
troponin and connexin 43. These proteins are essential for muscle contraction. The same 
difficulty arises with the generation of cardiomyocytes in vitro, demonstrating that an 
effective approach for cardiac regeneration must include both specialized cells in a three-
dimensional support or scaffold that provides the physical properties necessary for 
contraction. However, because of the heterogeneous population residing in the 
myocardium, attempts have focused on the generation of vascular replacements for larger 
vessels such as arteries. The utilisation by Dr. Taylor’s group of a decellularisation method 
in mouse heart yielded encouraging findings in relation to the generation of bio-artificial 
hearts. They decellularised the hearts by coronary perfusion with detergents, preserving the 
underlying extracellular matrix and producing an acellular, perfusable vascular architecture 
with competent acellular valves and intact chamber geometry. They mimicked the 
composition of cardiac cells by reseeding these constructs with cardiac or endothelial cells. 
The group maintained eight constructs for up to 28 days by coronary perfusion in a 
bioreactor that simulated cardiac physiology, observing macroscopic contractions by day 4. 
By day 8, under physiological load and electrical stimulation, the constructs generate a 
pump function equivalent to around 2% of adult or 25% of 16-week foetal heart function in a 
modified working heart preparation (Ott et al., 2008). 
Research by Dr. Christopher Breuer and Dr. Toshiharu Shinoka on tissue engineered 
vascular grafts (TEVG) is in the process of clinical translation for congenital cardiovascular 
diseases. In the United States, around 1 in 100 infants is expected to have heart defects, i.e., 
around 36,000 infants per year. Ten percent of these cases—over 3,600 infants—result in 
death. TVEGs are biodegradable synthetic scaffolds made of the same material as absorbable 
sutures and seeded with the individual’s own cells. The scaffold degrades by hydrolysis, 
eventually leaving only the living vessel in the patient. Bone marrow aspiration is used to 
harvest the cells, inserting the needle through the cortex of the spinal bone and marrow. The 
marrow is drawn up and separated by density centrifugation, yielding BMCs that are 
directly seeded onto the scaffold by pipetting. The seeded scaffold is then incubated in the 
patient’s plasma for two hours to attach cells to the scaffold. The graft is then ready for 
implantation. The whole process takes only a few hours, allowing a viable TEVG to be 
obtained on the same day as the cell harvesting (Nuti, 2010).  
www.intechopen.com
Therapeutic Approaches in Regenerative Medicine  
of Cardiovascular Diseases: From Bench to Bedside 
 
81 
8. Conclusion 
There have been numerous clinical trials of cell therapies for CVDs, and several problems 
have been identified. Questions that remain to be addressed in translational research from 
animals to humans concern the cell type, preparation time, delivery, cell number and 
optimization. The measurement of results must also be resolved, including the efficacy 
assessment method and length of follow-up. Nevertheless, the potential therapeutic 
contribution of adult stem cells is enormous. hESCs have been widely studied in relation to 
heart disease, but their use in cell therapy has been limited, in part due to ethically-based 
restrictions on research with this cell type in some countries and the lack of adequate 
funding. 
With regard to iPSCs, the most important and immediate advances have been in relation to 
drug discovery, in the context of an urgent need for new approaches to meet the increasing 
incidence of myocardial infarction and heart failure in ageing populations. The number of 
novel drugs entering the market for heart disease is decreasing, whereas investment by the 
pharmaceutical industry in this area continues to increase, underlining the need for patents 
to safeguard the intellectual property of research groups and provide them with sufficient 
financial support to run clinical trials. 
Criteria established by international scientific organizations such as the European Society of 
Cardiology and the American Society of Cardiology must be followed by researchers who 
address these issues. The correct design of future clinical trials is of particular importance 
before clinical stem cell therapy can be widely applied. In this regard, the International 
Society of Stem Cell Research (ISSCR, 2011) is taking the exceptional step of developing 
guidelines for patients, researchers and physicians, establishing safety procedures and 
providing patients worldwide with information to meet their concerns and describe their 
legal rights. 
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